Zebei Lu
YOU?
Author Swipe
View article: The Effect of <i>α</i> ‐Mangostin on the Pharmacokinetic Profile of Tofacitinib in Rats Both In Vitro and In Vivo
The Effect of <i>α</i> ‐Mangostin on the Pharmacokinetic Profile of Tofacitinib in Rats Both In Vitro and In Vivo Open
This study investigated the effects of α ‐mangostin ( α ‐MG) on the pharmacokinetics of tofacitinib in vitro and in vivo, aiming to recommend its appropriate application in clinical practice. To investigate the values of IC 50 and inhibiti…
View article: Drug–drug interactions between epidermal growth factor receptor tyrosine kinase inhibitors and rivaroxaban in vitro and in vivo
Drug–drug interactions between epidermal growth factor receptor tyrosine kinase inhibitors and rivaroxaban in vitro and in vivo Open
Background Tyrosine kinase inhibitor (TKI) and rivaroxaban co-administration is common for patients with cancer and venous thromboembolism. However, the drug–drug interactions (DDIs) between epidermal growth factor receptor (EGFR) TKIs and…
View article: Assessments of <scp>CYP</scp>‐Inhibition‐Based Drug–Drug Interactions Between Tofacitinib and Lipid‐Lowering Agents in Rats Both In Vitro and In Vivo
Assessments of <span>CYP</span>‐Inhibition‐Based Drug–Drug Interactions Between Tofacitinib and Lipid‐Lowering Agents in Rats Both In Vitro and In Vivo Open
Tofacitinib is a widely used medication for the treatment of arthritis. It has been reported that some patients experience abnormal cholesterol levels following treatment, leading to recommendations for the coadministration of lipid‐loweri…
View article: Computational and Experimental Investigation of Antidiabetic Drugs on Tofacitinib Metabolism: Molecular Docking, in vitro, and in vivo Studies
Computational and Experimental Investigation of Antidiabetic Drugs on Tofacitinib Metabolism: Molecular Docking, in vitro, and in vivo Studies Open
Gliquidone and linagliptin significantly altered the pharmacokinetics of tofacitinib in vitro and in vivo. This study demonstrated the drug-drug interactions between linagliptin, gliquidone, and tofacitinib, highlighting the need for clini…
View article: Unlocking Pan-Cancer Detection with Phenyl-β-D-Glucuronide&nbsp;Like Exogenous Agent and AI-Driven Induced Breath Analysis for Non-Invasive Early Discovery
Unlocking Pan-Cancer Detection with Phenyl-β-D-Glucuronide Like Exogenous Agent and AI-Driven Induced Breath Analysis for Non-Invasive Early Discovery Open
View article: Unlocking Pan-Cancer Detection with Phenyl-β-D-Glucuronide Like Exogenous Agent and Induced Breath Analysis for Non-Invasive Early Discovery
Unlocking Pan-Cancer Detection with Phenyl-β-D-Glucuronide Like Exogenous Agent and Induced Breath Analysis for Non-Invasive Early Discovery Open
The urgent need for a non-invasive, universally applicable cancer detection method has never been more critical. In response to the pressing demand, we presents the discovery of phenyl-β-D-glucuronide, a natural compound, for tumor detecti…
View article: The Impact of Baohuoside I on the Metabolism of Tofacitinib in Rats
The Impact of Baohuoside I on the Metabolism of Tofacitinib in Rats Open
Our study has demonstrated the presence of drug-drug interactions between baohuoside I and tofacitinib, which may arise upon pre-administration of tofacitinib. Altogether, our data indicated that an interaction existed between tofacitinib …
View article: Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by <scp>UPLC‐MS</scp>/<scp>MS</scp>
Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by <span>UPLC‐MS</span>/<span>MS</span> Open
Background Lenvatinib is a multitargeted tyrosine kinase inhibitor used in the treatment of a variety of solid tumors. This study aims to investigate the potential pharmacokinetic interactions between lenvatinib and various azoles (ketocon…
View article: Effects of bergapten on the pharmacokinetics of macitentan in rats both in vitro and in vivo
Effects of bergapten on the pharmacokinetics of macitentan in rats both in vitro and in vivo Open
Macitentan was approved by the United States Food and Drug Administration (FDA) in 2013 for the treatment of pulmonary arterial hypertension (PAH). Bergapten is a furanocoumarin that is abundant in Umbelliferae and Rutaceae plants and is w…
View article: Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib <scp>in vivo</scp> and <scp>in vitro</scp> by <scp>UPLC‐MS</scp>/<scp>MS</scp>
Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib <span>in vivo</span> and <span>in vitro</span> by <span>UPLC‐MS</span>/<span>MS</span> Open
Background As a pan‐HER tyrosine kinase inhibitor with a promising application prospect, poziotinib is likely to be coadministered with Schisandrins in clinical treatment due to its anticancer activities. Methods Eighteen Sprague–Dawley ra…